Skip to main content

Vagina Disease

0
Pipeline Programs
3
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Origin Sciences
Origin SciencesUK - Cambridge
1 program
Quantification of human DNA retrieved and DNA fragmentation profile.N/A1 trial
Active Trials
NCT05709119Completed45Est. Jul 2024
Origin
OriginRUSTON, LA
1 program
Quantification of human DNA retrieved and DNA fragmentation profile.N/A
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
undefinedN/A1 trial
Active Trials
NCT04887636Completed1,000Est. Jul 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Origin SciencesQuantification of human DNA retrieved and DNA fragmentation profile.
UNION therapeuticsundefined

Clinical Trials (2)

Total enrollment: 1,045 patients across 2 trials

NCT05709119Origin SciencesQuantification of human DNA retrieved and DNA fragmentation profile.

Feasibility of the Oricol™ Sampling Device to Retrieve Vagina Mucus (Wall) Samples for Genomic & Epigenetic Analysis.

Start: Jan 2024Est. completion: Jul 202445 patients
N/ACompleted

Baseline Study of Vaginal Microbiota in Healthy Chinses Female Population

Start: May 2021Est. completion: Jul 20221,000 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.